November 8, 2016
Here's a look at some of the noteworthy hepatitis C (HCV) research being presented at The Liver Meeting 2016 in Boston from Nov. 11 to 15. The conference will gather hepatologists from around the world and feature some of the latest research and developments in the field of hepatitis C.
Take a sneak peak at some conference highlights:
Researchers will present updates on a program and care model known as ECHO (Extension for Community Healthcare Outcomes), which aims to improve health outcomes in communities. The session will highlight the effectiveness of the ECHO model and how it can help improve hepatitis C care around the world. Specifically, the presenters will describe how to start a new ECHO project and where to obtain resources and technical assistance.
This session will give a "state-of-the-art" update on providing care for the more challenging communities living with hepatitis C by discussing clinical data and offering practical tips on patient management and best treatment options in the direct-acting antiviral (DAA) era. The presenters will help identify optimal treatment, particularly for patients with chronic kidney disease and those who inject drugs, and suggest how to improve cure rates.
Even though we have highly effective direct-acting antivirals that can cure hepatitis C, accessing and prescribing these medications can be a major obstacle to care, particularly due to restrictions set by many state Medicaid providers. This panel will bring together different stakeholders to discuss how to help resolve this problem.
Here are some other notable studies from the abstracts book:
Check back during and after the conference for our news and analysis.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Before and After Sex Worked as Well as Daily PrEP in Preventing HIV|
|For Transgender Women, PrEP Is Safe to Use With Estradiol as Feminizing Hormone Therapy, Study Says|
|This Week in HIV Research: Another Notch in the "Treatment as Prevention" Belt|
|Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant|
|Anthony Fauci Traces the HIV Research Path to U=U|